Who invested in MitoRx Therapeutics

7 rounds we have observed, with the 2 investors named in them. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Biotech

Raised 11 months ago

Funding summaryUpdated 26 Oct 2026

$13Mraised across 7 rounds since 2021, from 7 sources

$1.3MRound$2.4MRound$744KRound$625KRound$8.3MRound

Latest round: Round, $8.3MNov 2025
Step-upi: 13.3×
Investors: 2

See who backed them

The funding story

Each circle is a round, placed by date and sized by amount. The line above is the running total.

2022202320242025

$1.3MRound?Seed$2.4MRound$744KRound$625KRound?Venture$8.3MRound

First round: Round, $1.3M
Biggest round: $8.3M
Usual gap between rounds: 7 months

The rounds

Nov 2025
Round$8.3M
No investor was named in the report.
Shares issued, filed with Companies House (SH01); no report of this raise yet
Nov 2024
VentureAmount undisclosed1 new
- Future Planet Capital
Source recorded
Mar 2024
Round$625K
No investor was named in the report.
Shares issued, filed with Companies House (SH01); no report of this raise yet
Oct 2023
Round$744K
No investor was named in the report.
Shares issued, filed with Companies House (SH01); no report of this raise yet
Mar 2023
Round$2.4M
No investor was named in the report.
Shares issued, filed with Companies House (SH01); no report of this raise yet
Apr 2022
SeedAmount undisclosed1 new
- Oxford Technology (S)EIS Fund
Reported by Oxford Technology Management
Dec 2021
Round$1.3M
No investor was named in the report.
Shares issued, filed with Companies House (SH01); no report of this raise yet

Funding filed with regulators

MitoRx Therapeutics filed 13 raises, $14M in all. Filings say how much was sold and to how many investors; they never name the investors.

Dec 2025$2.2MUK share allotment
Nov 2025$6.2MUK share allotment
Dec 2024$1.0MUK share allotment
Apr 2024$156KUK share allotment
Mar 2024$470KUK share allotment
Oct 2023$744KUK share allotment
Mar 2023$2.4MUK share allotment
Mar 2022$332KUK share allotment
Feb 2022$156KUK share allotment
Feb 2022$292KUK share allotment
Jan 2022$148KUK share allotment
Jan 2022$137KUK share allotment
Dec 2021$266KUK share allotment

Founders and team

From MitoRx Therapeutics's own website: 1 founder, 11 on the team.

Jon Rees PhDCo-founder & Chief Executive Officer

Rick Cousins PhDChief Discovery Officer
Xavier Jacq PhDChief Scientific Officer
Alexander Fink BScNon-Executive Director
Aurelie Le FeuvrePrincipal Biology Lead & Programme Manager
Barbara Di FiorePrincipal Scientist
Ciaran FealyPrincipal Scientist
David McGarryAssociate Director of Medicinal Chemistry
Mo Qatanani PhDChair
Quentin GuerangerDirector of Biology
Roberta TorregrossaPrincipal Medicinal Chemist & Co-inventor
Sam Fazeli PhDNon-Executive Director

AdvisersLubor Gaal PhD

Who was in which round

The busiest backers across the latest rounds. A filled square is a round they joined; a dark one, a round they led.

Round2021Seed2022Round2023Round2023Round2024Venture2024Round2025

Future Planet CapitalOxford Technology (S)EIS Fund

Everyone who backed them

Future Planet CapitalVC firm1round

Oxford Technology (S)EIS FundInvestment firm1round

Missing a round, or an investor who was in one? Tell us.

Also claim to have backed them

These 2 firms list MitoRx Therapeutics as a portfolio company on their own websites, but no report of a round names them. They are the firms' own claims, kept apart from the rounds above.